Jonathan I. Lieber - Nov 30, 2022 Form 4 Insider Report for APPLIED GENETIC TECHNOLOGIES CORP (AGTC)

Role: Chief Financial Officer
Signature: /s/ Stacie Aarestad, Attorney-in-fact
Stock symbol: AGTC
Transactions as of: Nov 30, 2022
Transactions value $: $0
Form type: 4
Date filed: 12/1/2022, 08:15 AM
Previous filing: Aug 24, 2022
Next filing: Jan 5, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AGTC	Stock Option (Right to Buy)	Disposed to Issuer		-202K	-100%		0	Nov 30, 2022	Common Stock	202K	$3.30	Direct	F1
transaction	AGTC	Stock Option (Right to Buy)	Disposed to Issuer		-155K	-100%		0	Nov 30, 2022	Common Stock	155K	$0.40	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Jonathan I. Lieber is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option.

Remarks:

Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 23, 2022, by and among Applied Genetic Technologies Corporation (the "Issuer"), Alliance Holdco Limited ("Parent") and Alliance Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), on November 30, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").